Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-06-19
2009-11-10
Bowman, Amy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S024300, C514S04400A
Reexamination Certificate
active
07615627
ABSTRACT:
This invention relates to the use of short nucleic acid molecules that modulate Aurora-B kinase (AurkB) expression. The invention includes compounds, compositions and methods useful for the modulation of expression and activity of genes involved in the AurkB pathway. In one embodiment, the present invention provides short nucleic acid molecules, such as siRNA, which can be used in treating, preventing, or inhibiting cancer, and any other proliferative disease, trait or condition, which respond to a reduction in AurkB expression in a cell or tissue. Such short nucleic acid molecules can be used alone or in combination with other treatments or therapies, including short nucleic acid molecules that modulate expression of EGFR.
REFERENCES:
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 2005/0267065 (2005-12-01), Dean et al.
patent: 2005-278472 (2005-10-01), None
patent: 2005-320351 (2005-11-01), None
patent: WO 02/090514 (2002-11-01), None
patent: WO 2004/070062 (2004-08-01), None
Scrittori et al., A Small C-Terminal Sequence of Aurora B Is Responsible for Localization and Function, 2005, Molecular Biology of the Cell, vol. 216, pp. 292-305.
Kang et al., Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo, 2006, Cancer Gene Therapy, 13, pp. 530-538.
Chieffi et al., Aurora B Expression Directly Correlates With Prostate Cancer Malignancy and Influence Prostate Cell Proliferation, 2006, The Prostate, 66, pp. 326-333.
Marciniak et al., Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells, 2004, Molecular Cancer Therapeutics, 3(12), pp. 1615-1621.
Tuschl et al., The siRNA user guide, Aug. 26, 2001 (on-line), retrieved Jan. 31, 2002, pp. 1, 3 and 5, Max Planck Institute for Biophysical Chemistry.
Holen et al., Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor, 2002, Nucleic Acids Research, vol. 30, No. 8, pp. 1757-1766.
Manoharan, Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery, and Mechanism of Action, 2002, Antisense & Nucleic Acid Drug Development, 12, pp. 103-128.
Briassouli et al., “Aurora-A Regulation of Nuclear Factor-kB Signaling by Phosphorylation of IkBα” Cancer Res., Feb. 2007, 67(4), pp. 1689-1695.
Yang et al, “Aurora-A Kinase Regulates Telomerase Activity Through c-Myc in Human Ovarian and Breast Epithelial Cells”, Cancer Res., 2004, 64, pp. 463-467.
Soncini et al. “PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity”, Clin. Cancer Res., 2006, 12(13), pp. 4080-4089.
Livak et al., “Analysis of Relative Gene Expression Data Using Real Time Quantitative PCR and the 2ΔΔ CTMethod,” Methods, 2001, 25, pp. 402-408.
Srikantan et al., “HEPSIN” Inhibits Cell Growth/Invasion in Prostate Cancer Cells, Cancer Res., 2002, 62, pp. 6812-6816.
Yarrow et al., “A high-Throughput Cell Migration Assay Using Scratch Wound Healing, A Comparison of Image-Based Readout Methods”, BMC Biotechnology, 2004, 4(21), pp. 1-9.
Klein et al., “A New Quantitative Test Method for Cell Proliferation Based on Detection of the Ki-67 Protein”, J Material. Sci: Materials in Med., 2000, 11, pp. 125-132.
Du Manoir et al., “Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization”, Human Genetics, 1993, 90, pp. 590-610.
Kim et al., “Synthetic dsRNA Dicer-substrates Enhance RNAi Potency and Efficacy”, Nature Biotechnology, 2005, 23, pp. 222-226.
Weinstat-Saslow et al., “Angiogenesis and Colonization in the Tumor Metastatic Process: Basic and Applied Advances”, FASEB Journal, 1994, 8, pp. 401-407.
Lee et al., “Targeting Aurora Kinases for the Treatment of Prostate Cancer”, Cancer Res., May 2006, 66, pp. 4996-5002.
Chieffi et al., “Aurora B Expression Directly Correlates with Prostate Cancer Malignancy and Influence Prostate Cell Proliferation”, Prostate, 2006, 66, pp. 326-333.
Rojanala et al., “The Mitotic Serine Kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer”, Mol. Cancer Ther., 2004, 66, pp. 451-457.
Kurai et al., “Expression of Aurora Kinases A and B in Normal, Hyperplastic, and Malignant Human Endometrium: Aurora B As a Predictor for Poor Prognosis in Endometrial Carcinoma”, Human Pathol., 2005, 36, pp. 1281-1288.
Zhou et al. “Genetic Variation in Human NPY Expression Affects Stress Response and Emotion” Nature, Apr. 2008, 452, pp. 997-1002.
Joshi et al., “P276-00, A Novel Cyclin-Dependent Inhibitor Induces G1-G2 Arrest, Shows Antitumor Activity on Cisplatin-Resistant Cells and Significant in Vivo Efficacy in Tumor Models”, Mol. Can. Ther., Mar. 2007, 6(3), pp. 926-934.
Sasai et al., “Aurora-C kinase is a novel chromosomal passenger protein that can complement aurora-B kinase function in mitotic cells” Cell Motility and the Cytoskeleton, 2004, 59, pp. 249-263.
Hirota et al., “Aurora-A and an Interacting Activator, the LIM Protein Ajuba, Are Required for Mitotic Commitment in Human Cells,” Cell, 2003, 114, pp. 585-598.
Dutertre et al., “Phosphorylation of CDC25B by Aurora-A at the Centrosome Contributes to the G2-M Transition,” J. Cell. Sci., 2004, 117(12), pp. 2523-2531.
Carmena et al., “The Cellular Geography of Aurora Kinases”, Nat. Rev. Mol. Cell Biol., 2003, 4, pp. 842-854.
Schumacher et al., “AIR -2 : An Aurora/lpl1-related protein Kinase Associated with Chromosomes and Midbody Microtubules Is Required for Polar Body Extrusion and Cytokinesis in Caenorhabditis elegans Embryos” J. Cell. Biol., 1998, 143, pp. 1635-1646.
Terada et al., “AIM-1: a mammalian midbody-associated protein required for cytokinesis”, EMBO J., 1998, 17, pp. 667-676.
Giet et al, “Drosophila Aurora B Kanse Is Required for Histone H3 Phosphorylation and Condensin Recruitment during Chromosome Condensation and to Organize the Central Spindle during Cytokinesis”, J. Cell Biol., 2001, 152, pp. 669-681.
Giet et al., “Aurora kinases, aneuploidy and cancer, a coincidence or a real link?”, Trends. Cell Biol. 2005, 5, pp. 241-250.
Duesberg et al., “Cancer Drug Resistance: The Central Role of the Karyotype,” Drug Resist Updat., 2007, 10, pp. 51-58.
Keen et al., “Aurora-kinase Inhibitors As Anticancer Agents”, Nature Rev., 2004, 4, pp. 927-936.
Ota et al., “Increased Mitotic Phosphorylation of Histone H3 Attributable to AIM-1/Aurora-B Overexpression Contributes to Chromosome Number Instability”, Cancer Res., 2002, 62, pp. 5168- 5177.
Vischioni et al., “Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients”, Mol. Cancer Ther., 2006, 5, pp. 2905-2913.
Smith et al., “Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability”, Br. J. Cancer, 2005, 93, pp. 719-729.
Liu et al., “Aurora-A Abrogation of p53 DNA Binding and Transactivation activity by Phosphorylation of Serine 215”, J Biol Chem., 2004, 279, pp. 52175-52182.
Katayama et al., “Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53”, Nat. Genetics, 2004, 36, pp. 55-62.
Ouchi et al., “BRCA1 Phosphorylation by Aurora-A in the Regulation of G2 to M Transition”, J Biol. Chem., 2004, 279, pp. 19643-19648.
Andrews, “Aurora kinases: shining lights on the therapeutic horizon?” Oncogene, 2005, 24, pp. 5005-5015.
Ditchfield et al., “Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2 and Cenp-E to kinetochores”, J. Cell Biol., 2003,
Addepalli Murali Krishna
Reddy Vidyadhar Eswar Chandra Gopavaram
Bowman Amy
Foley & Lardner LLP
Reliance Life Sciences PVT. Ltd.
LandOfFree
RNA interference mediated inhibition of aurorakinase B and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNA interference mediated inhibition of aurorakinase B and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of aurorakinase B and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4083655